Abbott Laboratories (ABT)
Abbott Laboratories (ABT) Q2 2026 Earnings Call Transcript
Abbott Laboratories (ABT) Q2 2026 Earnings Call Transcript
Abbott Q2 Earnings & Revenues Top Estimates, Stock Up in Pre-market
ABT tops Q2 earnings and revenue estimates and lifts 2026 EPS guidance, while Medical Devices and Cancer Diagnostics fuel growth despite Nutrition weakness.
Abbott Laboratories shares jump as earnings beat estimates and company raises 2026 outlook
Abbott Laboratories (NYSE:ABT) shares rose nearly 11% on Thursday after the healthcare company reported second quarter 2026 results that topped Wall Street expectations and raised its full-year adjusted earnings guidance. The company posted adjusted diluted earnings per share of $1.31 for the quarter, ahead of analyst expectations of $1.28.
Abbott Laboratories Q2 Earnings Call Highlights
Abbott Laboratories NYSE: ABT reported second-quarter 2026 comparable sales growth of 4.8% and adjusted earnings per share of $1.31, with Chairman and Chief Executive Officer Robert Ford saying results marked an acceleration from the prior two quarters.
Here's What Key Metrics Tell Us About Abbott (ABT) Q2 Earnings
Although the revenue and EPS for Abbott (ABT) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Abbott (ABT) Q2 Earnings and Revenues Top Estimates
Abbott (ABT) came out with quarterly earnings of $1.31 per share, beating the Zacks Consensus Estimate of $1.28 per share. This compares to earnings of $1.26 per share a year ago.
What Investors Don't Understand About Abbott Laboratories
The market still treats Abbott Laboratories (NYSE:ABT | ABT Price Prediction) like a bond proxy with a stethoscope: baby formula, branded generics, and a metronomic dividend.
Ora Banda delivers record gold quarter as ‘DRIVE to 300’ expansion gathers momentum
Ora Banda Mining Ltd (ASX:OBM, OTC:ESGFF) has closed FY2026 with record quarterly gold production, strong cash flow and a larger resource base. The company...
Reasons to Retain Abbott Stock in Your Portfolio for Now
ABT is banking on emerging-market pharmaceutical growth and innovation in Nutrition, but macro pressures and currency swings remain key challenges.
Abbott's Q2 Earnings on Deck: How Should You Play the Stock Now?
ABT heads into Q2 earnings results with growth expected across Diagnostics, Devices and EPD, while Nutrition remains a drag. Here's what could shape the results.
Unlocking Q2 Potential of Abbott (ABT): Exploring Wall Street Estimates for Key Metrics
Beyond analysts' top-and-bottom-line estimates for Abbott (ABT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.
Brokers Suggest Investing in Abbott (ABT): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
